Oral Influenza Vaccine
Seasonal Influenza
Phase 2Active
Key Facts
About Vaxart
Vaxart's mission is to transform global health by developing oral recombinant pill vaccines that generate mucosal and systemic immunity. The company's core strategy leverages its proprietary delivery platform to create vaccines that are easier to administer, do not require cold-chain logistics, and could potentially reduce transmission of viruses. While still in clinical development, Vaxart aims to address significant unmet needs in infectious diseases with a more accessible and potentially more effective vaccine format.
View full company profileTherapeutic Areas
Other Seasonal Influenza Drugs
| Drug | Company | Phase |
|---|---|---|
| mRNA-based Influenza Vaccine | Sanofi | Phase 3 |
| mRNA-1010/1011 | Moderna | Phase 3 |
| Standalone Seasonal Influenza Vaccine | Novavax | Phase 3 |
| LUNAR®-FLU (ARCT-2138) | Arcturus Therapeutics | Phase 1 |